Medical CBRN Defense Consortium (MCDC) Other Transaction Agreement (OTA) Request for Information (RFI) – CoV Pandemic Response
Issue Date: March 19, 2020
Response: Offerors are strongly encouraged to submit within 48 hours of the issue date of this RFI. However, this is an open RFI, and submissions will be accepted through the end date.
End Date: May 31, 2020
The purpose of this special notice is to obtain information via White Papers from both MCDC members and other interested industry/academia partners in response to the novel Coronavirus (2019-nCoV) pandemic in the United States (U.S.). The Government is requesting White Papers with a focus on the following areas:
- Diagnostics/Monitoring: Medical diagnostic devices, with specific emphasis on Point-of-Care diagnostics (e.g. CLIA waived), under development and capable of diagnosing 2019- SARS-CoV-2, and achieving Emergency Use Authorization (EUA) from the Food and Drug Administration (FDA) within the next one to four (1-4) months.
- Surveillance: Surveillance methods and associated devices for 2019-SARS-CoV-2 screening. Any technology that can enhance the understanding of disease progression in COVID-19 infected patients is also of interest, including physiologic monitoring and other vital signs indicators, portable technology that enhances patient care in non-hospital settings, and technology that improves sample collection.
Note: Offerors can consider pursuing Assay and/or Device development efforts that could be used for health surveillance, medical diagnostics, or potentially both. Medical diagnostics efforts need to ensure that they meet required regulatory pathways.
- Information systems and technology the Government can use in a handheld Point-of-Care device to collect, screen, collate, report, and monitor disease infection and pandemic spread on a micro and macro level.
- Therapeutics: Drugs and/or drug/device combinations, or platforms currently under development demonstrating efficacy in post-exposure, pre- and post-symptomatic studies for any CoV strain, and capable of achieving EUA from the FDA within the next three (3) months for this ongoing SARS-CoV-2 pandemic. Antibody technologies, accelerating the discovery, development, manufacturing, and prediction of success for these technologies, can also be considered.
- Prophylactics: Drugs or vaccines currently under development demonstrating pre-exposure in vivo efficacy or in vitro activity against any or all strains of CoV. Antibody technology, accelerating the discovery, development, manufacturing and prediction of success for these technologies can be considered.
- Clinical Trials: Opportunities to expeditiously conduct clinical trials for any technology that will require evaluation for FDA approval, will be considered.
This request is Market Research to determine the capability of the industrial base to respond to the 2019-nCoV pandemic. At this time, funding has not been identified for any prototype projects under this request.
Entities are encouraged to provide innovative products and technologies that in the short term (1-6 months), can be rapidly deployed to combat the current pandemic. Long-term solutions (6 months and beyond) are not requested at this time.
It is expected the proposed solutions will be submitted to, and receive FDA EUA.
By submission of a White Paper in response to this request, the offeror agrees that even if marked as proprietary information in the White Paper, the Government has full authority to distribute the White Paper to any other Government agency requesting it. The proprietary information will be handled accordingly. White Papers will not be returned to the member and may be retained indefinitely by the Government. The White Papers will not be subjected to a source selection review process, therefore, no White Paper Feedback will be provided.
MCDC Membership: The OTA Consortium model allows for increased, streamlined collaboration between the Government and Consortium membership. The OTA Consortium model is a unique acquisition tool that allows for more open communication and emphasizes engaging a diversified range of membership – from academia to industry suppliers. The MCDC Consortium model operates via a single set of terms and conditions through the single-point contracting agent for the Consortium, or Consortium Management Firm (CMF). As a result, the OTA process decreases acquisition time and cost, enabling rapid technology and prototype solutions. Membership in the MCDC Consortium allows for networking with stakeholders including Government, Industry, and Academia.
Interested parties can be directed to https://www.medcbrn.org/how-to-join/ to obtain information on membership. Companies that are part of the Academia, US Defense Industrial Base, as well as new and emerging non-traditional defense contractors, are encouraged to join the MCDC and participate in Federally-funded R&D projects. Any questions should be addressed to the CMF, Advanced Technology International (ATI), at MCDC@ati.org.
For this request, submission is open to all entities of the US Defense Industrial Base, not just MCDC members. Should a non-MCDC member be selected for award, that entity would be required to join the MCDC prior to award execution.
White Paper Response Date and Submission Instructions:
Considering the urgency to find solutions, offerors are highly encouraged to respond within 48 hours of the issuance of this RFI. However, responses received beyond the 48 hour window will also be reviewed by the Government. Once responses are submitted, they cannot be updated. It is anticipated this Special Pandemic Response RFI will remain open through May 31, 2020, and may be extended if needed.
White Papers must be submitted using the BIDS portal at the link provided below:
- Please visit this site to register if you have not already. Registration is required before submission.
- Upon WP submission, a receipt confirmation, including a unique reference number, will be provided by email. The email will come from email@example.com(check your spam folder if you do not receive notification).
Exhibit 1, Suggested White Paper Template, provides offerors with a template that may be used to respond to this RFI. The format is not required. Further, if the offeror has responded to other COVID related Government solicitations or requests for information, the offeror may submit in its original format under this RFI, so long as the offeror identifies the Government solicitation or request for information where the solution was previously submitted. Please also identify to which Objective Area you are submitting to. Please note that the size limit is currently 5mb per submission.
FREQUENTLY ASKED QUESTIONS
Please forward all other inquiries to firstname.lastname@example.org
Who is allowed to submit proposals?
This RFI is open to the public, offerors are not required to be a MCDC member or have previously been a DoD contractor. All contractors can submit to the RFI regardless of their nontraditional/traditional defense contractor status.
Registration and submissions are only accepted through the BIDS portal: https://ati.acqcenter.com/MCDC/BIDS.NSF/Start?ReadForm and is only allowable from US-based IP addresses.
If you are a foreign firm and have a US-based affiliate, please use that entity to submit.
If you are a foreign firm and don’t have a US-based affiliate, please send your submission directly to email@example.com and we will upload your submission.
What is the response time/window?
Responses are requested to be submitted within the first 48 hours (through 16:00 21 March), but will be accepted through 31 May.
Is there a budgetary constraint?
ATI has not been informed of any budget constraints. You are encouraged to respond to the RFI with relevant information per the suggested template. If the Government believes the solution(s) is applicable, someone will reach out to you to discuss further.
What technologies apply to this RFI?
The Government encourages all responses for solutions to the sub-objectives laid out. If you believe your organization can provide a solution(s), please provide a response to the RFI. The Government will reach out to you if they believe a proposed solution(s) is feasible.
How many sub-objectives can be selected to propose to?
There is no limit on how many sub-objectives your company can submit to. However, we do recommend that one response per solution be considered, even if that means submitting multiple times. This would offer the opportunity to expand on each solution within the RFI.
Is there a required format or template needed to submit?
While there is no mandatory format or template, be mindful of the suggested page count (6). Please note that the size limit is currently 5mb per submission (including figures).